EssilorLuxottica announced six-month interim clinical trial results on September 22, 2026, showing that Essilor Stellest 2.0 spectacle lenses achieved treatment effects of 0.51 D for myopia progression and 0.21 mm for axial elongation compared to single-vision lenses in children. The randomized, double-masked study in China demonstrated that the newer lenses matched the 12-month efficacy of first-generation models in half the time.
Clinical Trial Results and Treatment Speed
Max technology. According to EssilorLuxottica, mean myopia progression stayed close to 0 D after six months in the treatment group. Company executives noted that the speed and magnitude of the treatment response outpace anything previously recorded in their research programs.
“The magnitude and speed of the treatment response observed at six months are very encouraging and have not been previously observed across our Stellest clinical research ever,” said Davide Schinetti, chief operating and R&D officer at EssilorLuxottica.
Prof. Yang Xiao, principal investigator at the Zhongshan Ophthalmic Center at Sun Yat-sen University in China, stated that the lenses achieved the same level of refraction and axial length control in six months that previous versions reached in one year. Xiao presented these findings during a satellite symposium at the World Society of Paediatric Ophthalmology and Strabismus Subspecialty Day in London, held during the European Society of Cataract and Refractive Surgeons Congress.
Pro Tip: When evaluating myopia management options for pediatric patients, clinicians often look closely at both refraction (measured in diopters) and axial elongation (measured in millimeters) to gauge how well a lens slows eye growth.
Patient Compliance and Spectacle Adaptation
Beyond optical efficacy, the interim analysis tracked how children adjusted to wearing the new lenses daily. More than 90% of children across both study groups wore their spectacles for more than 12 hours per day, seven days a week.
Wearer adaptation rates matched those of standard single-vision lenses. Specifically, 98% of participating children fully adapted to wearing the Stellest 2.0 spectacles within one week.
Global Clinical Research and Prior Studies
The trial in China marks the first randomized, double-masked clinical evidence for Stellest 2.0 lenses generated in the country. EssilorLuxottica noted that these data align with findings from an earlier randomized contralateral crossover clinical trial conducted in Singapore, which was published in Translational Vision Science & Technology in 2025.
The study remains active as researchers continue monitoring participants to evaluate long-term safety and efficacy. The prespecified one-year analysis will serve as the trial’s primary efficacy endpoint.
Frequently Asked Questions
What are Essilor Stellest 2.0 lenses?
What were the main findings of the six-month interim trial?
At six months, the lenses demonstrated treatment effects of 0.51 D for myopia progression and 0.21 mm for axial elongation compared to single-vision lenses, performing as well as first-generation lenses do after a full year.
How well did children adapt to the lenses?
Over 90% of children wore the spectacles for more than 12 hours daily, and 98% fully adapted to them within one week.
Want to stay updated on the latest developments in pediatric eye care and clinical trials? Subscribe to our newsletter or explore our related articles on myopia management.